Investments
72Portfolio Exits
11Funds
12Latest NRW.Bank News
Dec 14, 2021
Emergence Therapeutics AG , a Duisburg, Germany-based biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers, closed an €87m series A financing round. The round was led by Pontifax Venture Capital and includes RA Capital Management, OrbiMed Advisors, Surveyor Capital (a Citadel company) and Hadean Ventures as new investors as well as existing investors Kurma Partners, NRW.BANK, High-Tech Gründerfonds, Gründerfonds Ruhr and Bpifrance through its InnoBio 2 fund. Management also participated in the round. Proceeds from this funding round will be used to advance the company’s antibody drug conjugate (ADC) targeting Nectin-4 to clinical proof-of-concept as well as the development of additional ADC programs. Led by Jack Elands, CEO, Emergence is advancing ETx-22, a next-generation Nectin-4 ADC which has been optimized to increase efficacy and minimize toxicity. ETx-22 has shown to be selective for tumor-expressed Nectin-4 and has tumor-specific deconjugation resulting in reduced toxicity. ETx-22 will initially be developed for bladder and triple negative breast cancer as well as malignancies with medium and low nectin-4 expression levels, including ovarian, head and neck and lung cancer. Proceeds from the financing will also support the development of a pipeline of further ADC candidates. As part of the financing round, the Company announced the appointment of the following members to the Supervisory Board: Irina Staatz-Granzer (independent member, designated Chairperson) Roy Amariglio (OrbiMed Advisors) Matthew Hammond (RA Capital Management) Olivier Martinez (Bpifrance) Anke Caßing (High-Tech Gründerfonds)
NRW.Bank Investments
72 Investments
NRW.Bank has made 72 investments. Their latest investment was in DropFriends as part of their Seed on July 7, 2022.
NRW.Bank Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
7/7/2022 | Seed | DropFriends | Yes | 1 | ||
2/16/2022 | Series B - III | CryoTherapeutics | No | 3 | ||
1/19/2022 | Unattributed | everwave | Yes | 1 | ||
12/7/2021 | Series A | |||||
2/11/2021 | Seed VC |
Date | 7/7/2022 | 2/16/2022 | 1/19/2022 | 12/7/2021 | 2/11/2021 |
---|---|---|---|---|---|
Round | Seed | Series B - III | Unattributed | Series A | Seed VC |
Company | DropFriends | CryoTherapeutics | everwave | ||
Amount | |||||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 1 | 3 | 1 |
NRW.Bank Portfolio Exits
11 Portfolio Exits
NRW.Bank has 11 portfolio exits. Their latest portfolio exit was phenox on April 21, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/21/2022 | Acquired | 4 | |||
12/23/2021 | Acquired | 5 | |||
10/4/2021 | Acquired | 2 | |||
Date | 4/21/2022 | 12/23/2021 | 10/4/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 | 5 | 2 |
NRW.Bank Fund History
12 Fund Histories
NRW.Bank has 12 funds, including Seed Fund III Aachen.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
4/12/2018 | Seed Fund III Aachen | $25M | 1 | ||
12/31/2013 | NRW.BANK.Seed Fonds Zwei GmbH & Co. KG | Early-Stage Venture Capital | Closed | 1 | |
12/31/2011 | NRW.BANK.Venture Fonds Zwei GmbH & Co. KG | Early-Stage Venture Capital | Closed | $107.82M | 1 |
12/31/2009 | NRW.BANK.Kreativwirtschaftsfonds GmbH & Co. KG | ||||
1/31/2007 | Seed-Fonds fuer die Region Aachen |
Closing Date | 4/12/2018 | 12/31/2013 | 12/31/2011 | 12/31/2009 | 1/31/2007 |
---|---|---|---|---|---|
Fund | Seed Fund III Aachen | NRW.BANK.Seed Fonds Zwei GmbH & Co. KG | NRW.BANK.Venture Fonds Zwei GmbH & Co. KG | NRW.BANK.Kreativwirtschaftsfonds GmbH & Co. KG | Seed-Fonds fuer die Region Aachen |
Fund Type | Early-Stage Venture Capital | Early-Stage Venture Capital | |||
Status | Closed | Closed | |||
Amount | $25M | $107.82M | |||
Sources | 1 | 1 | 1 |
NRW.Bank Team
2 Team Members
NRW.Bank has 2 team members, including current Managing Director, Claas Heise.
Name | Work History | Title | Status |
---|---|---|---|
Claas Heise | DTSI | Managing Director | Current |
Dietmar P Binkowska | Chief Executive Officer | Former |
Name | Claas Heise | Dietmar P Binkowska |
---|---|---|
Work History | DTSI | |
Title | Managing Director | Chief Executive Officer |
Status | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.